View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 30, 2020

Results from Sanofi’s Kevzara trial allows a more targeted approach for its final stages

By Victoria Smith

On 27 April, Regeneron and Sanofi published provisional results from the Phase II section of an ongoing Phase II/III clinical trial assessing Kevzara (sarilumab), in hospitalised patients with severe or critical respiratory illness caused by Covid-19.

The randomised trial compared the drug, administered intravenously at two different doses of 200mg and 400mg, with placebo. Read more here.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy